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 A survey on endometrial cancer management in Italy was performed.
 This survey demonstrate a signiﬁcant improvement over the last decades in Italy.
 High-risk cases only, properly selected, could be referred to reference centers.a r t i c l e i n f o
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Introduction: Endometrial carcinoma (EC) is a frequent cancer in developed countries, but with evi-
dence for discrepant clinical management. Under the auspices of the Italian Society of Gynecologic
Oncology (SIOG), we conducted a survey among Italian centers with 20 surgeries for gynecological
cancer per year, trying to depict a reliable picture of EC management in our country. Methods: The
questionnaire focused on preoperative/surgical staging and adjuvant treatment. Of the 283 question-
naires delivered, 35% were sent back. Results: Diagnostic hysteroscopy is performed in 78% of centers. In
clinical stage I, 52% adopt a laparotomic access, 15% totally laparoscopic, 9% laparoscopic/vaginal, 2%
vaginal, 22% tailored approach. Elective use of laparoscopy signiﬁcantly differs between institutions
(p < 0.001): 40% (20 EC/yr) vs. 12% (<20). Pelvic and aortic lymphadenectomy is selectively performed
by 77% and 68% of centers, respectively, depending on pre/intraoperative factors. Non-endometrioid
histology, poor-grade and deep myoinvasion are indicated as the highest-risk factors. Adjuvant ther-
apy is given to pathologically node-negative patients by 60%, and to intermediate-risk patients by 47%.
Elective adjuvant treatment is still radiotherapy, but chemotherapy is adopted, mostly combined with
radiation, by 40%. There is a multidisciplinary team in 64% of centers, but in 59% adjuvant treatment is to
be administered outside the institution. Conclusions: These data demonstrate a signiﬁcant improvement
in the clinical care achieved over the last decades in Italy. Centralization of EC treatment would not beuto Nazionale per lo Studio e
” e IRCCS, Via M. Semmola,
ecologia@istitutotumori.na.it
by Elsevier Ltd. All rights reserved.
S. Greggi et al. / International Journal of Surgery 12 (2014) 1038e1044 1039feasible neither useful. High-risk cases could be selected by an appropriate clinical screening, and these
only referred to reference centers.
© 2014 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Endometrial carcinoma (EC) is the fourth most common cancer
among women in Italy, accounting for 5% of all malignant neo-
plasms with 8200 estimated new cases for 2013 (incidence trend
1996e2010: þ0.7%). About 70% of these patients are diagnosed at
an early stage, resulting in a favorable prognosis, with 5-year
overall survival rate of 77% (survival trend 1990e2007: þ4%) [1].
Despite being the most common gynecological cancer in
developed countries, there is evidence for many differences and
discrepancies in the clinical management [2].
Both the preoperative and surgical staging are still object of
controversies. There is no general agreement on basic questions,
such as the routine use of diagnostic hysteroscopy, and on which
imaging technique should be considered as indispensable. With
respect to surgery, lymph node dissection (LND) represents the
main point of discussion, based on the lack of evidence of its
therapeutic impact [3,4]. When and how should it be performed?
Various are the algorithms (if any) adopted by different centers,
including or not intraoperative frozen sections of the uterine
specimen.
Also, the indications to adjuvant treatment (and which?) are not
uniform and seem to be more dependent on local habits and re-
sources rather than on data of evidence. Such a clinical scenario
reﬂects the scientiﬁc uncertainties still present but may be also
related to missing update of information [5].
Under the auspices of the Italian Society of Gynecologic
Oncology (SIOG), we have conducted a survey among the Italian
centers involved in the gynecologic cancer care, trying to depict a
reliable picture of the EC management in our country.Fig. 1. Surgical staging and treatment: A) Overall; B) General Hospitals with <20 cases
of cancer/year; C) Teaching Hospitals/Cancer Centers with >20 cases of cancer/year
(Legend: AH, abdominal hysterectomy; TLH, total laparoscopic hysterectomy; LAVH,
laparoscopy-assisted vaginal hysterectomy; VH, vaginal hysterectomy; Tailored, based
on patient/disease characteristics).2. Methods
Data were collected by means of a questionnaire concerning
speciﬁc diagnostic and therapeutic options. This questionnaire was
mailed to the gynecologic centers listed in the Italian National
Health Service (NHS) directory. Selected were only those centers
with at least 20 surgical operations for gynecological cancer, per
year.
Of the 283 questionnaires delivered, 99 (35%) were ﬁlled in and
sent back by the end of January 2013. Sixty-one percent and 39%
were from Northern and Central-Southern Italian institutions,
respectively. Most questionnaires (78%) were from General Hospi-
tals, while the remaining 21% from Teaching Hospitals/Cancer
Centers. Overall, only 42% of centers have treated more than 20
cases of EC in the last year.
The questionnaire focused on three principal areas: 1) preop-
erative staging (evaluation of: cervical inﬁltration, depth of myo-
metrial invasion, lymph node status, endometrial tumor size,
dosage of serum tumor markers, revision of external pathological
diagnosis); 2) surgical staging and therapy (type of hysterectomy in
FIGO Stage I, histotype, tumor size and inﬁltration of cervical canal
under consideration for surgical management, peritoneal cytology,
intraoperative frozen sections, criteria for LND, surgical conduct in
the presence of obvious intraperitoneal metastasis); 3) adjuvant
treatment (which categories are considered at high- and
intermediate-risk, any change in the risk assessment in the absence
of LND, indications for adjuvant therapy in node-negative patients,adjuvant treatment in high- and intermediate-risk, presence of an
intra-institutional department of pathology, radiotherapy and
medical oncology, capability of performing a brachytherapy, where
and by whom the choice of any adjuvant treatment is made).3. Results
3.1. Preoperative staging
The great majority of centers believe that the evaluation of
myometrial invasion (94%), cervical canal (93%), lymph node status
Fig. 2. Indication to LND: A) Pelvic LND; B) Aortic LND (Legend: LND, lymphadenectomy; MI, myometrial inﬁltration; UPSCeCCC, uterine papillary-serous/clear cell carcinoma; LN,
lymph node).
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preoperative staging. In this respect, there are no signiﬁcant dif-
ferences among the institution either the case-volume patterns.
The diagnostic techniques routinely adopted (alone or in combi-
nation) are the following: hysteroscopy (78%), transvaginal ultra-
sound (TVUS) (61%), magnetic resonance imaging (MRI) (52%),
computed tomography (CT) (40%).
Pre-surgical dosage of tumor serum markers is routinely per-
formed in 78% of centers. In these centers, CA125, alone or in
combination, is always included in the preoperative workup.
Combined CA125 and CA19-9 dosage is performed in 52%, while
25% of centers adopt a markers panel (CA125, CA19-9, CA15-3,
CEA ± AFP and TPA).
Revision of external pathological diagnosis is routinely per-
formed in 51% of centers to verify histotype and grade in referred
patients.
3.2. Surgical staging and therapy
Peritoneal cytology is routinely performed in 94% of institutions.
About the surgical treatment in clinical stage I, 52% of centers
adopt a laparotomic access, 15% a totally laparoscopic, 9% a com-
bined laparoscopic and vaginal, and 2% a vaginal access. The
remaining 22% tailor the surgical approach e i.e. they modify the
access e depending on the disease and patient characteristics
(Fig. 1). Tailoring surgical approach and the elective use of lapa-
roscopy signiﬁcantly differ between the institution pattern: 33% vs.14% (p ¼ 0.010), and 40% vs. 12% (p < 0.001) for institutions treating
20 and <20 EC cases/year, respectively (Fig. 1). The type of hys-
terectomy performed in case of clinical FIGO stage I disease is
extrafascial (pubovesical cervical fascia removed) in 80% of in-
stitutions, simple (intrafascial, pubovesical cervical fascia pre-
served) hysterectomy in 18%, type B radical (paracervix removed at
the intersection of ureter with the uterine artery) hysterectomy in
1%; bilateral salpingo-oophorectomy is routinely performed.
In the case of serous and clear cell histology, the laparotomic
approach is believed mandatory by 61% of centers, while additional
surgical procedures necessary by 94% (pelvic LND: 91%; omentec-
tomy: 72%; appendectomy: 56%; aortic LND: 54%). In the presence
of inﬁltration of the cervical canal the surgery conduct is a type B
radical hysterectomy in 76%, and a type C radical hysterectomy in
14%, while is still an extrafascial hysterectomy in the remaining 10%
of centers (none treating 20 cases per year). The majority (75%) of
centers do not take into consideration the endometrial tumor size
for the surgical management. Only 31% of centers routinely perform
an intraoperative frozen section analysis on the uterine specimen
(81% of Teaching Hospitals/Cancer Centers). Twenty-six percent do
not consider it valid and necessary, 13% do not have such a facility,
16% consider frozen section useful only if macroscopic examination
of the myometrial and cervical canal inﬁltration is doubtful, and
13% adopt different criteria.
When considering the retroperitoneal LND, 24% of centers are
used to perform a lymph node sampling, 72% as systematic pro-
cedure (20 pelvic nodes; 10 aortic nodes), while 3% resection of
Fig. 3. Adjuvant therapy in FIGO stage I with negative lymph nodes: A) Overall; B) General Hospitals with <20 cases of cancer/year; C) Teaching Hospitals/Cancer Centers with >20
cases of cancer/year (Legend: AT, adjuvant therapy; MI, myometrial inﬁltration; LVSI, lymph vascular space involvement; UPSCeCCC, uterine papillary-serous/clear cell carcinoma).
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forming pelvic LND, 23% of centers perform it routinely, while the
remaining do it, depending on the following factors: >50% myo-
metrial inﬁltration (86%), serous or clear cell histology (80%), poorly
differentiated tumors (77%), moderately differentiated tumors (4%),
suspicious nodes (3%) (Fig. 2A). Aortic LND is never performed in
28% of institutions, routinely in 2%, while 68% do it, depending on
the following factors: pelvic nodes suspected or positive at frozen
sections (100%), serous or clear cell histology (66%) (Fig. 2B). Sig-
niﬁcant differences do not emerge in this respect through the
comparison of centers by institution and case-volume patterns.
With respect to cases with intra-abdominal spread, surgerywith
cytoreductive intent is believed inappropriate by only 8% of centers.Ninety percent consider that the presence of obvious intraperito-
neal metastasis changes the surgical behavior, by the following
additional procedures: omentectomy (89%), appendectomy (57%),
pelvic (53%) and aortic LND (35%).
3.3. Adjuvant treatment
The prerequisite was to establish which category of patients,
based on ﬁnal pathology report, is to be considered at enough risk
of recurrence to justify an adjuvant treatment. First of all, the
“special” histology is considered a high-risk factor, regardless of
stage, by over 80% of centers (84% and 82% for serous and clear cell
histotype, respectively) (100% of Teaching Hospital/Cancer Centers
Fig. 4. Adjuvant therapy in intermediate-risk: A) Overall; B) General Hospitals with
<20 cases of cancer/year; C) Teaching Hospitals/Cancer Centers with >20 cases of
cancer/year (Legend: AT, adjuvant therapy).
Table 1
First-choice adjuvant treatment in the high-risk group of patients.
Adjuvant treatment n %
External radiotherapy ± brachytherapy 44 45
External radiotherapy ± brachytherapy þ sequential chemotherapy 22 23
Concurrent chemo-radiation ± brachytherapy 15 15
Chemotherapy 2 2
Brachytherapy 0 0
Hormone therapy 0 0
Multiple options 14 15
Missing 2 2
Total 99 100
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centers (96%), consider FIGO stage III and IV (intra-abdominal),
completely cytoreduced, at high-risk. The invasion of cervical
stroma per se (FIGO stage II) is considered a high-risk parameter by
71% of centers, and adjuvant brachytherapy is judged adequate by
all of them. Looking at the disease conﬁned to the uterine corpus,
the association of poor differentiation (G3) and deep myometrial
invasion (>50%) is indicated as the highest risk subgroup for the
endometrioid histotype by the majority of centers (82%). Interest-
ingly, G3 alone is considered a high-risk factor by only 37% in the
presence of <50%myometrial invasion, as well as >50%myometrial
invasion in well or moderately-well differentiated tumors is shown
as a high-risk marker by 34% of centers. The intermediate-risk is
often identiﬁed by the association of a moderate differentiation
(G2) and >25% myometrial invasion (IB-G2: 53%; IA-G2: 49%), but
also by G3 in the presence of <25% (33%) and 25e50% myometrial
invasion (44%).
Not performing a (at least pelvic) LND and the evidence of
lymph vascular space invasion (LVSI) affects the risk grouping in
51% and 52% of centers, respectively. Adjuvant therapy, however, is
given by 60% of centers even in the case of negative lymph nodes
after a systematic pelvic LND in pathologically FIGO stage I disease.
In particular, among these centers, adjuvant therapy is considered
indicated in the presence of: G3 (57%), >50%myometrial inﬁltration
(39%), “special” histotype (26%), LVSI (17%) (Fig. 3).
Forty-seven percent of centers also include the intermediate-
risk in the group for which adjuvant treatment is indicated. The
proportions signiﬁcantly differ between General Hospitals with
<20 cases of cancer/year (82%), and Teaching Hospitals/Cancer
Centers with >20 cases of cancer/year (16%) (Fig. 4). The ﬁrst-choice
adjuvant treatment in high-risk patients is external radiation
therapy (with or without brachytherapy) in 45% of centers.
Chemotherapy is included, mostly combined with radiation, by 40%
of centers (Table 1). Adjuvant options in the intermediate-risk pa-
tients are listed in Table 2 (Table 2).
Another issue concerns the decision making process. A pathol-
ogy service/department is available in the same institution in 83%
of centers, and a dedicated pathologist (exclusively assigned to
gynecologic oncology) in only 18%. Is each case discussed within a
team, or any therapeutic decision is taken by a single specialist?
There is a multidisciplinary team in 64% of centers, and in most
(84%) of the reference centers. This team is composed by a gyne-
cologist, a medical oncologist, and a radiation oncologist in 55% of
cases; by a gynecologist and a medical oncologist in 26%, by a gy-
necologist and a radiation oncologist in 14%, and by a medical
oncologist and a radiation oncologist in 5%. In the absence of a
team, the single specialist in charge of therapeutic decisions is the
medical oncologist (52%), the gynecologist (45%), and the radiation
oncologist (3%). Amedical oncology department is present in 89% of
centers, while a radiotherapy department is available in the same
institution in only 42% of centers, with brachytherapy facilities in
about two-third of cases (67%). These data justify the need for
performing adjuvant treatment outside the institution in the ma-
jority of centers (59%).
4. Discussion
As expected, many controversial aspects of EC management
have emerged from the present survey. EC is the most frequent
gynecological malignancy, and is treated in reference centers as
well as in general hospitals. This is why the authors, endorsed by
the Italian Society of Gynecologic Oncology (SIOG), decided to send
the questionnaire not only to leading institutions or to the Society
members but also to low case-volume centers. Overall, less than
half (42%) of responders have treated more than 20 EC cases in thelast year, and this likely reﬂects the actual disease management in
our country, as well as the geographical distribution of centers (61%
Northern, and 39% Central-Southern Italy). The 35% compliance (of
the 283 questionnaires sent, 99 were ﬁlled in and sent back) can be
Table 2
First-choice adjuvant treatment in the intermediate-risk group of patients.
Adjuvant treatment n %
External radiotherapy ± brachytherapy 20 20
External radiotherapy ± brachytherapy þ sequential chemotherapy 1 1
Concurrent chemo-radiation ± brachytherapy 1 1
Chemotherapy 1 1
Brachytherapy 2 2
Hormone therapy 0 0
As in high-risk 14 14
No therapy 52 53
Missing 8 8
Total 99 100
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ever, seems to be in the range of similar surveys reported in the
literature. Higher rates are generally observed when a question-
naire is selectively sent to leading centers, members of a Society, etc
(our questionnaire was sent to all hospital with at least 20 surgical
operations for gynecological cancer, per year).
The great majority (78%) of centers adopt hysteroscopy as a
diagnostic tool and part of the preoperative staging. This is in
contrast with the 6.2% reported about ten years ago in a similar
survey by leading centers of gynecological oncology in North
America [6], and reﬂects the different attitude with respect to
hysteroscopy between US and Europe. A European survey, per-
formed about ﬁfteen years ago on leading centers, showed, in fact, a
routine pre-surgical use of hysteroscopy in 32.9% of institutions [7].
Actually, hysteroscopy is usually included in international guide-
lines as the ﬁnal step in the diagnostic pathway, but differences still
remain [8e10]. Our data suggest that, at least in Italy, its use in
endometrial pathology is currently widespread. Abdomenepelvis
MRI or CT are not routinely included in the staging workup, but
performed, however, in about 50% of cases, with or without a
previous TVUS, with or without suspected cervical involvement
and/or extra-uterine spread. This seems to be unnecessary in many
cases [9], and it is likely to be relevant to a potential costebeneﬁt
analysis [11].
During the last decade, the surgical approach to EC has changed
with an increasing proportion of cases undergoing a laparoscopic
intervention [12,13]. Overall, 24% of centers declare to routinely
perform a laparoscopic (total or vaginally assisted) surgery, and a
further 22% to tailor the surgical approach depending on the pa-
tient and disease characteristics. In fact, the laparoscopic option (as
well as the indication to tailor the choice) is signiﬁcantly more
adopted in the high case-volume centers (40% and 33%, respec-
tively) compared to those with low case-volume (12% and 14%,
respectively) (p < 0.001 and p ¼ 0.010). This does not mean that
laparoscopic/robotic surgery has become the ﬁrst choice option in
EC. It is considered, however, in almost half of the cases, at least in
leading centers. In the case of serous papillary and clear cell tumors,
a laparotomic approach is believed mandatory by 61% of centers,
and the surgical staging is performed in accordance with the rules
deﬁned for ovarian cancer by 94% [14,15]. Also, regardless of his-
totype, in the presence of intra-abdominal spread, surgery with
cytoreductive intent is believed appropriate by 92% of centers. Both
these ﬁndings are representative of an adequate practice pattern
[8e10].
With respect to the type of hysterectomy, it is clear that, in
clinical FIGO stage I disease, there is no room anymore for a type
BeC radical hysterectomy (optioned by only one center), in accor-
dance with national and international recommendations [8e10].
On the other hand, 10% low case-volume centers believe that an
extrafascial hysterectomy is to be performed in the presence of
clinical inﬁltration of the cervical canal. It is still surprising,however, that 20.5% and 9.9%, respectively of leading European and
North American institutions had reported the same procedure as
the elective intervention in FIGO stage II disease [6,7].
One of the major issues in EC therapy is the value of LND.
Regardless of the ambiguous international guidelines [8e10], it is to
be underlined that the majority of centers (72%) consider LND,
when performed, as a systematic procedure (20 pelvic nodes;10
aortic nodes). Pelvic and aortic LND, however, is routinely per-
formed in 23% and 2% of institutions, respectively. Thus, the ma-
jority of centers perform it only in selective clinicalesurgical
conditions. This fact underlines that an algorithm based on pre-
operative but especially intraoperative ﬁndings is followed in most
centers. This is in contrast with the unavailability or non adoption
of intraoperative frozen section analysis on the uterine specimen in
70% of institutions (but in less than 20% of Teaching Hospitals/
Cancer Centers). In spite of the data recently generated [3,4], the
proportion of centers performing LND has not changed dramati-
cally over the last decades, at least looking at the Western Europe.
In 1995, pelvic LND was routinely performed in 24.4% of European
leading centers [7]. It is of interest to mention that a recent survey
conducted by the North-Eastern German Society of Gynecological
Oncology (NOGGO) in selected centers of 24 countries, showed a
different attitude with respect to routine LND among diverse
geographical macroareas: USeUK 35%, Asia 73%, Southern Europe
28%, Central Europe 56% [16].
As far as the adjuvant treatment is concerned, the major issue is
represented by the group of patients with the disease conﬁned to
the uterine corpus [5]. As expected, there is no general agreement
not only on which patients are to be considered at enough risk of
recurrence to justify an adjuvant therapy, but also onwhich therapy
is to be given and whether a lymph node negative status following
LND can spare further treatment in patients with high-risk tumors.
In fact, these controversies do reﬂect the uncertainties in the clin-
ical management felt in the health community worldwide. If
combined poor grade of differentiation and deep myometrial in-
vasion is indicated as the highest risk subgroup for the endome-
trioid histology by very most centers, only about one third of them
consider one of these a high-risk factor per se in the absence of the
other. In particular, deep myometrial inﬁltration seems to be
considered a high-risk factor per se in a lesser extent, compared to
that reported by similar surveys in the past years (83e89%) [6,7],
and our data conﬁrm the decreasing trend reported in a more
recent survey [17]. International recommendations usually
consider deep myometrial inﬁltration as an indication to adjuvant
therapy regardless of the presence of any additional prognosticator.
Different options including observation are, however, allowed even
within the same guideline [9]. About half of centers include the
intermediate-risk in the group for which adjuvant treatment is to
be administered, although this is true only in 16% of Teaching
Hospitals/Cancer Centers compared with 82% of General Hospitals
with low case-volume. Furthermore, the borders between high-
and intermediate-risk areas are deﬁnitely still unclear.
Sixty percent of centers give patients adjuvant therapy even in
the case of negative lymph nodes after a pelvic LND in pathological
FIGO stage I with additional high-risk factors. This rate is not very
different from 70 to 77% observed in the previous surveys [6,7]. It is
evident that such a clinical question is still to be answered. Two
international trials, one evaluating the need for adjuvant therapy in
node-negative patients (NCT01244789), the other (upcoming, Gy-
necologic Cancer Intergroup) addressing the role of LND as part of
the decisional tree, are expected to clarify this issue in the next
years.
The ﬁrst-choice adjuvant treatment in high-risk patients is still
external radiation (with or without brachytherapy) in 45% of cen-
ters. Chemotherapy, as sequential or concurrent, is added by a
S. Greggi et al. / International Journal of Surgery 12 (2014) 1038e10441044further 38%, while given alone by only 2%. As expected, there is
evidence for an increased use of additional chemotherapy
compared with the previous surveys (4e20%). The recent survey by
NOGGO conﬁrms such a trend with a 40% chemo-radiation in
Southern Europe [16].
From the present survey, emerges that there is a multidisci-
plinary team in 64% of centers, and inmost reference centers. These
data demonstrate a signiﬁcant improvement in the clinical care
achieved over the last decades in our country. Nevertheless, if a
medical oncology department is present in the same institution in
almost 90% of cases, a radiotherapy department/service is available
only in about 40% (including brachytherapy in less than 30%). These
data justify the need for performing adjuvant treatment outside the
institution in about 60% of centers, often in the absence of an
effective local-regional oncological network. Overall, the EC patient
management and, particularly, the decision making process at
speciﬁc clinical knots, can be critical, especially in non-reference
hospitals. This is due to controversial scientiﬁc issues still to be
solved, and to the lack of facilities and speciﬁc knowledge in the
peripheral, low case-volume centers. EC is, however, a relatively
frequent disease, and centralization of treatment would not be
feasible neither useful, surgical treatment of low-risk EC being
feasible in non-specialized centers. High-risk cases (non endome-
trioid, poorly differentiated, extrauterine spread) could be selected
if the clinical screening was appropriate, and these only referred to
experienced centers. Standardization of the clinical workup and
referral of selected cases to a network of centers (still to be iden-
tiﬁed) represent our next task.
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